{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:24:00Z","timestamp":1788387840696,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s40265-022-01809-w","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T02:57:31Z","timestamp":1669949851000},"page":"1727-1735","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria"],"prefix":"10.1007","volume":"82","author":[{"given":"Young-A","family":"Heo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,2]]},"reference":[{"issue":"3","key":"1809_CR1","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.htct.2020.06.006","volume":"43","author":"RD Cancado","year":"2021","unstructured":"Cancado RD, Araujo ADS, Sandes AF, et al. Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria. Hematol Transfus Cell Ther. 2021;43(3):341\u20138.","journal-title":"Hematol Transfus Cell Ther."},{"issue":"25","key":"1809_CR2","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1182\/blood.2021012860","volume":"139","author":"E Gavriilaki","year":"2022","unstructured":"Gavriilaki E, Peffault de Latour R, Risitano AM. Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond. Blood. 2022;139(25):3571\u201382.","journal-title":"Blood"},{"key":"1809_CR3","doi-asserted-by":"publisher","first-page":"204062072211146","DOI":"10.1177\/20406207221114673","volume":"13","author":"RSM Wong","year":"2022","unstructured":"Wong RSM. Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria. Ther Adv Hematol. 2022;13:20406207221114670.","journal-title":"Ther Adv Hematol."},{"issue":"11","key":"1809_CR4","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1080\/03007995.2021.1971182","volume":"37","author":"RH Bhak","year":"2021","unstructured":"Bhak RH, Mody-Patel N, Baver SB, et al. Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison. Curr Med Res Opin. 2021;37(11):1913\u201323.","journal-title":"Curr Med Res Opin"},{"key":"1809_CR5","unstructured":"Apellis Pharmaceuticals Inc. EMPAVELI\u2122 (pegcetacoplan) injection, for subcutaneous use: US prescribing information 2021. https:\/\/pi.apellis.com\/files\/PI_Empaveli.pdf. Accessed 31 Oct 2022."},{"key":"1809_CR6","unstructured":"European Medicines Agency. ASPAVELI 1080 mg solution for infusion: summary of product characteristics. 2021. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/aspaveli. Accessed 31 Oct 2022."},{"issue":"9","key":"1809_CR7","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s00277-022-04903-x","volume":"101","author":"RSM Wong","year":"2022","unstructured":"Wong RSM, Pullon HWH, Amine I, et al. Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria. Ann Hematol. 2022;101(9):1971\u201386.","journal-title":"Ann Hematol"},{"issue":"11","key":"1809_CR8","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/ajh.25960","volume":"95","author":"C de Castro","year":"2020","unstructured":"de Castro C, Grossi F, Weitz IC, et al. C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab. Am J Hematol. 2020;95(11):1334\u201343.","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"1809_CR9","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1182\/blood-2021-147493","volume":"138","author":"RS Wong","year":"2021","unstructured":"Wong RS, Navarro JR, Comia NS, et al. Efficacy and safety of pegcetacoplan treatment in complement-inhibitor na\u00efve patients with paroxysmal nocturnal hemoglobinuria: results from the phase 3 PRINCE study [abstract no. 606 and presentation]. Blood. 2021;138(Suppl 1):606\u20138.","journal-title":"Blood"},{"issue":"11","key":"1809_CR10","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","volume":"384","author":"P Hillmen","year":"2021","unstructured":"Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021;384(11):1028\u201337.","journal-title":"N Engl J Med"},{"key":"1809_CR11","unstructured":"Bogdanovic A, Wong R, Navarro JR, et al. Efficacy and safety of pegcetacoplan treatment in complement-inhibitor na\u00efve patients with paroxysmal nocturnal hemoglobinuria: Results from the phase 3 PRINCE study [abstract no. OS15-02]. In: 48th Annual Meeting of the European Society for Blood and Marrow Transplantation 2022."},{"issue":"Suppl 1","key":"1809_CR12","first-page":"606","volume":"138","author":"R Wong","year":"2022","unstructured":"Wong R, Navarro JR, Comia NS, et al. Efficacy and safety of pegcetacoplan treatment in complement-inhibitor na\u00efve patients with paroxysmal nocturnal hemoglobinuria: results from the phase 3 PRINCE study [abstract no. 508]. Blood. 2022;138(Suppl 1):606.","journal-title":"Blood"},{"key":"1809_CR13","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1097\/01.HS9.0000846216.47601.df","volume":"6","author":"A Risitano","year":"2022","unstructured":"Risitano A, Wong R, Al-Adhami M, et al. Categorizing hematological response to pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria: a post hoc analysis of the phase 3 PRINCE study data [abstract no. P833 and poster]. Hemasphere. 2022;6:727\u20138.","journal-title":"Hemasphere"},{"issue":"Suppl 3","key":"1809_CR14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/01.HS9.0000844104.86321.a6","volume":"6","author":"D Gomez-Almaguer","year":"2022","unstructured":"Gomez-Almaguer D, Wong R, Dumagay T, et al. Effect of pegcetacoplan on quality of life in complement-inhibitor na\u00efve patients with paroxysmal nocturnal hemoglobinuria: results from the phase 3 PRINCE study [abstract no. S303 and poster]. Hemasphere. 2022;6(Suppl 3):204\u20135.","journal-title":"Hemasphere."},{"issue":"Suppl 1","key":"1809_CR15","first-page":"189","volume":"193","author":"RP Peffault de Latour","year":"2021","unstructured":"Peffault de Latour RP, De Castro CM, Szer J, et al. Superiority of pegcetacoplan compared to eculizumab in patients with paroxysmal nocturnal hemoglobinuria, regardless of prior transfusion requirement: analysis at 16-weeks of PEGASUS phase 3 randomized trial [abstract no BSH2021-PO-207 and poster]. Br J Haematol. 2021;193(Suppl 1):189\u201390.","journal-title":"Br J Haematol"},{"issue":"Suppl 2","key":"1809_CR16","first-page":"704","volume":"5","author":"A Risitano","year":"2021","unstructured":"Risitano A, Weitz IC, Castro CMD, et al. Categorized hematologic response to pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria: post hoc analysis of PEGASUS phase 3 randomized trial data [abstract no. PB1477]. Hemasphere. 2021;5(Suppl 2):704\u20135.","journal-title":"Hemasphere."},{"issue":"Suppl 1","key":"1809_CR17","first-page":"198","volume":"193","author":"A Roth","year":"2021","unstructured":"Roth A, Hochsmann B, Griffin M, et al. Effect of pegcetacoplan on quality of life in patients with paroxysmal nocturnal hemoglobinuria from the PEGASUS phase 3 trial comparing pegcetacoplan to eculizumab [abstract no. BSH2021-PO-217 and poster]. Br J Haematol. 2021;193(Suppl 1):198\u20139.","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"1809_CR18","first-page":"149","volume":"56","author":"A Roth","year":"2021","unstructured":"Roth A, Lenderking WR, Sarda SP, et al. Improvements in fatigue and physical function evaluated through changes in clinical outcomes in paroxysmal nocturnal hemoglobinuria: post-hoc analyses from the PEGASUS study [abstract no. O137 and presentation]. Bone Marrow Transplant. 2021;56(Suppl 1):149\u201350.","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"1809_CR19","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s00277-022-04887-8","volume":"101","author":"D Cella","year":"2022","unstructured":"Cella D, Sarda SP, Hsieh R, et al. Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase III PEGASUS study. Ann Hematol. 2022;101(9):1905\u201314.","journal-title":"Ann Hematol"},{"issue":"9","key":"1809_CR20","doi-asserted-by":"publisher","first-page":"e648","DOI":"10.1016\/S2352-3026(22)00210-1","volume":"9","author":"RP de Latour","year":"2022","unstructured":"de Latour RP, Szer J, Weitz I, et al. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. Lancet Haematol. 2022;9(9):e648\u201359.","journal-title":"Lancet Haematol"},{"issue":"Suppl 2","key":"1809_CR21","first-page":"263","volume":"5","author":"A Roth","year":"2021","unstructured":"Roth A, Hochsmann B, Griffin M, et al. Effect of pegcetacoplan on quality of life in patients with paroxysmal nocturnal hemoglobinuria: week 48 of PEGASUS phase 3 trial comparing pegcetacoplan to eculizumab [abstract no. EP595 and poster]. Hemasphere. 2021;5(Suppl 2):263\u20134.","journal-title":"Hemasphere."},{"issue":"Suppl 1","key":"1809_CR22","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1182\/blood-2021-153127","volume":"138","author":"D Cella","year":"2021","unstructured":"Cella D, Johansson P, Ueda Y, et al. Clinically important difference for the FACIT-Fatigue scale in paroxysmal nocturnal hemoglobinuria: a derivation from international PNH registry patient data [abstract]. Blood. 2021;138(Suppl 1):1952.","journal-title":"Blood"},{"key":"1809_CR23","unstructured":"Mulherin BP, Yeh M, Al-Adhami M, et al. Hemoglobin, lactate dehydrogenase, and FACIT-Fatigue normalization rates in patients treated with pegcetacoplan: results from the PEGASUS and PRINCE phase 3 clinical trials [abstract no. P578 and poster]. In: 48th Annual Meaning of the European Society for Blood and Marrow Transplantation. 2022."},{"issue":"Suppl 1","key":"1809_CR24","first-page":"135","volume":"197","author":"J Panse","year":"2022","unstructured":"Panse J, Daguindau N, Okuyama S, et al. Pegcetacoplan treatment in patients with paroxysmal nocturnal hemoglobinuria and baseline hemoglobin levels at or above 10 g\/dL [abstract no. BSH22-PO90 and poster]. Br J Haematol. 2022;197(Suppl 1):135\u20136.","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"1809_CR25","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1182\/blood-2021-147988","volume":"138","author":"A Risitano","year":"2021","unstructured":"Risitano A, Wong RS, Al-Adhami M, et al. Categorized hematologic response to pegcetacoplan and correlations with quality of life in patients with paroxysmal nocturnal hemoglobinuria: post hoc analysis of data from phase 1b, phase 2a, and phase 3 trials [abstract no. 508]. Blood. 2021;138(Suppl 1):1104\u20136.","journal-title":"Blood"},{"issue":"Suppl 3","key":"1809_CR26","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1097\/01.HS9.0000846240.50953.6f","volume":"6","author":"I Weitz","year":"2022","unstructured":"Weitz I, Al-Adhami M, Min J, et al. Patients with paroxysmal nocturnal hemoglobinuria treated with pegcetacoplan show improvements in D-dimer normalization and decrease in incidence of thrombosis [abstract no. P839 and poster]. Hemasphere. 2022;6(Suppl 3):733\u20134.","journal-title":"Hemasphere."},{"key":"1809_CR27","unstructured":"Dingli D, Yeh M, Al-Adhami M, et al. Sustained D-dimer normalization and reduced incidence of thrombosis events in pegcetacoplan treated patients with paroxysmal nocturnal hemoglobinuria: week 48 interim results from the 307 long term extension study [abstract no. 372 and poster]. In: Thrombosis and Hemostasis Summit of North America 2022."},{"issue":"12b Suppl.","key":"1809_CR28","first-page":"S8","volume":"26","author":"M Bektas","year":"2020","unstructured":"Bektas M, Copley-Merriman C, Khan S, et al. Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease. J Manag Care Spec Pharm. 2020;26(12b Suppl.):S8\u201314.","journal-title":"J Manag Care Spec Pharm"},{"key":"1809_CR29","unstructured":"National Institute for Health and Care Excellence. Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria-technology appraisal guidance. 2022. https:\/\/www.nice.org.uk\/guidance\/ta778. Accessed 1 Sep 2022."},{"issue":"Suppl 1","key":"1809_CR30","doi-asserted-by":"publisher","first-page":"S342","DOI":"10.1016\/S2152-2650(21)01796-1","volume":"21","author":"V Sharma","year":"2021","unstructured":"Sharma V, Weitz I, Koprivnikar J, et al. Injection site reactions at week 48 in the randomized phase 3 PEGASUS trial of pegcetacoplan compared with eculizumab for individuals with paroxysmal nocturnal hemoglobinuria [abstract no. MDS-135 and poster]. Clin Lymphoma Myeloma Leuk. 2021;21(Suppl 1):S342.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"18","key":"1809_CR31","first-page":"1725","volume":"385","author":"P Hillmen","year":"2021","unstructured":"Hillmen P, Risitano AM, Peffault de Latour R. Pegcetacoplan versus eculizumab in PNH. Reply N Engl J Med. 2021;385(18):1725\u20136.","journal-title":"Reply. N Engl J Med."},{"issue":"Suppl 3","key":"1809_CR32","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1097\/01.HS9.0000846244.47350.40","volume":"6","author":"R Wong","year":"2022","unstructured":"Wong R, Fishman J, Wilson K, et al. A matching-adjusted indirect comparison of the efficacy of pegcetacoplan using PRINCE trial data versus ravulizumab and eculizumab in complement-na\u00efve patients with paroxysmal nocturnal hemoglobinuria [abstract no. P840 and poster]. Hemasphere. 2022;6(Suppl 3):734\u20135.","journal-title":"Hemasphere."},{"key":"1809_CR33","unstructured":"Mahajerin A, Al-Adhami M, Savage J, et al. Pegcetacoplan patient compliance rates in PEGASUS and PRINCE phase 3 trials compared to published oral medication compliance rates in literature [abstract no. BSH22-EP53 and poster]. In: British Society for Haematology Annual Scientific Meeting 2022."},{"issue":"13","key":"1809_CR34","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2217\/cer-2022-0076","volume":"11","author":"Z Hakimi","year":"2022","unstructured":"Hakimi Z, Wilson K, McAughey E, et al. The cost-effectiveness, of pegcetacoplan compared with ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria, in a UK setting. J Comp Effect Res. 2022;11(13):969\u201385.","journal-title":"J Comp Effect Res."},{"issue":"Suppl 1","key":"1809_CR35","doi-asserted-by":"publisher","first-page":"4956","DOI":"10.1182\/blood-2021-153190","volume":"138","author":"S Anderson","year":"2021","unstructured":"Anderson S, Talbird S, Fishman J. Cost per responder analysis for pegcetacoplan and eculizumab in the treatment of adults with paroxysmal nocturnal hemoglobinuria [abstract no. 901]. Blood. 2021;138(Suppl 1):4956\u20137.","journal-title":"Blood"},{"issue":"1 Suppl","key":"1809_CR36","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1016\/j.jval.2021.11.418","volume":"25","author":"S Anderson","year":"2022","unstructured":"Anderson S, Talbird SE, Fishman J, et al. Budget impact of pegcetacoplan, a complement C3 inhibitor, for the treatment of paroxysmal nocturnal hemoglobinuria in US adults [abstract no. POSB145 and poster]. Value Health. 2022;25(1 Suppl):S89.","journal-title":"Value Health."}],"updated-by":[{"DOI":"10.1007\/s40265-023-01898-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01809-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01809-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01809-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T03:51:30Z","timestamp":1685677890000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01809-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":36,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1809"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01809-w","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-023-01898-1","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"10 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2023","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-023-01898-1","URL":"https:\/\/doi.org\/10.1007\/s40265-023-01898-1","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Young-A Heo is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}